Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.60 |
| ▸ | RAB9A | P51151 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | NPC1 | O15118 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.46 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | NOS1 | P29475 | 1/20 | 0.42 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4683220 | 0.82 | ALDH1A1 (0.53) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL28329584 | 0.81 | ALDH1A1 (0.53) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL8880291 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL6693601 | 0.81 | ALDH1A1 (0.51) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL4687160 | 0.80 | ALDH1A1 (0.55) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL2643079 | 0.80 | RAB9A (0.47) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| Bromide SCHEMBL9297985 | 0.79 | ALDH1A1 (0.50) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL2642531 | 0.78 | MAPT (0.38) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL4688142 | 0.78 | PLA2G4A (0.45) | ALDH1A1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL965863 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7427635-B2 | Substituted hydantoins | HOFFMANN-LA ROCHE INC. (US) | 2008-09-23 | — | — | US | claimed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | claimed |
| EP-1781649-A2 | SUBSTITUTED HYDANTOINS | F. Hoffmann-Roche AG (CH) | 2007-05-09 | — | — | EP | claimed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | claimed |
| WO-2006018188-A2 | SUBSTITUTED HYDANTOINS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-23 | — | — | WO | claimed |
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3415519-A1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | F. Hoffmann-La Roche AG (CH) | 2018-12-19 | — | — | EP | disclosed |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3055315-B1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2018-07-25 | — | — | EP | disclosed |
| EP-3055315-B1 | THIAZOLOPYRIMIDINONES AS MODULATORS OF NMDA RECEPTOR ACTIVITY | HOFFMANN LA ROCHE (CH) | 2018-07-25 | — | — | EP | disclosed |
| US-9988400-B2 | Thiazolopyrimidinones and methods of use thereof | GENENTECH, INC. (US) | 2018-06-05 | — | — | US | disclosed |
| EP-1781649-B1 | SUBSTITUTED HYDANTOINS | HOFFMANN LA ROCHE (CH) | 2008-08-13 | — | — | EP | disclosed |
| EP-1781649-A2 | SUBSTITUTED HYDANTOINS | F. Hoffmann-Roche AG (CH) | 2007-05-09 | — | — | EP | disclosed |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | US | disclosed |
| US-20060041146-A1 | Substituted hydantoins | HOFFMANN-LA ROCHE AG | 2006-02-23 | — | — | US | disclosed |
| WO-2006018188-A2 | SUBSTITUTED HYDANTOINS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-23 | — | — | WO | disclosed |
| EP-1598349-A1 | NOVEL 2-PYRIDINECARBOXAMIDE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-11-23 | — | — | EP | disclosed |
| CN-1188411-C | Oxime derivatives and agricultural chemicals containing same | DAINIPPON INK & CHEMICALS (JP) | 2005-02-09 | — | — | CN | disclosed |
| CN-1281452-A | Oxime derivatives and agricultural chemicals containing same | DAINIPPON INK & CHEMICALS (JP) | 2001-01-24 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041146-A1 | Substituted hydantoins | HNMT, MAPK6, KYNU | ALDH1A1 552/4885MAPT 2100/4885RAB9A 764/4885 |
| US-10647731-B2 | Thiazolopyrimidinones and methods of use thereof | TPMT, THPO, CYP11B2 | ALDH1A1 159/4885MAPT 1190/4885RAB9A 3839/4885 |
| US-20180244694-A1 | THIAZOLOPYRIMIDINONES AND METHODS OF USE THEREOF | TPMT, THPO, CYP11B2 | ALDH1A1 159/4885MAPT 1190/4885RAB9A 3839/4885 |
| US-20060258701-A1 | Novel 2-pyridinecarboxamide derivatives | GCKR, GCK, HK2 | ALDH1A1 1249/4885MAPT 4612/4885RAB9A 3535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.